Climb Bio (CLYM) announced that the company will be added to the NASDAQ Biotech Index (NBI) as part of the annual reconstitution of the 2024 Nasdaq indexes. Climb Bio’s inclusion in the Nasdaq Biotechnology Index will be effective prior to market open on Monday, December 23, 2024.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CLYM:
- Climb Bio Inc. Shifts Focus to Immune-Mediated Diseases
- Climb Bio reports Q3 EPS (13c) vs (15c) last year
- Climb Bio appoints Williams as Chair of the board of directors
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
